Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a

Implications for a novel adjuvant in vaccine design

Edward L. Morgan, Brandon N. Morgan, Elisabeth A. Stein, Elizabeth L. Vitrs, Marilyn L. Thoman, Sam Sanderson, Joy A. Phillips

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A conformationally biased, agonist of human C5a65-74 (EP67) was assessed for its adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) type cytokines from C5a receptor (CD88)-bearing antigen presenting cells (APC). EP67 did not induce the release of these cytokines from splenic APCs obtained from C5a receptor knockouts (CD88-/-). Serum from mice immunized with EP67-ovalbumin (OVA) contained high OVA-specific antibody (Ab) titers [IgG1, IgG2a (IGg2c), IgG2b]. Mice receiving OVA alone produced only IgG1 Abs, indicating the ability of EP67 to induce a Th1-like Ab class switch. Spleen cell cultures from wild type mice but not CD88-/- mice showed an enhanced OVA-specific proliferative response in vitro. These results indicate the ability of EP67 to drive a Th1-mediated immune response and its potential use as a unique adjuvant.

Original languageEnglish (US)
Pages (from-to)463-469
Number of pages7
JournalVaccine
Volume28
Issue number2
DOIs
StatePublished - Dec 11 2009

Fingerprint

vaccine adjuvants
Anaphylatoxin C5a Receptor
ovalbumin
Ovalbumin
agonists
Vaccines
mice
adjuvants
cytokines
Immunoglobulin G
receptors
Cytokine Receptors
antibodies
antigen-presenting cells
Immunoglobulin Isotypes
Antigen-Presenting Cells
splenocytes
cell culture
Spleen
Cell Culture Techniques

Keywords

  • Adjuvants
  • Antibodies
  • C5a
  • Vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a : Implications for a novel adjuvant in vaccine design. / Morgan, Edward L.; Morgan, Brandon N.; Stein, Elisabeth A.; Vitrs, Elizabeth L.; Thoman, Marilyn L.; Sanderson, Sam; Phillips, Joy A.

In: Vaccine, Vol. 28, No. 2, 11.12.2009, p. 463-469.

Research output: Contribution to journalArticle

Morgan, Edward L. ; Morgan, Brandon N. ; Stein, Elisabeth A. ; Vitrs, Elizabeth L. ; Thoman, Marilyn L. ; Sanderson, Sam ; Phillips, Joy A. / Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a : Implications for a novel adjuvant in vaccine design. In: Vaccine. 2009 ; Vol. 28, No. 2. pp. 463-469.
@article{93f27a0cf3444273bed486f27cb9a0ea,
title = "Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: Implications for a novel adjuvant in vaccine design",
abstract = "A conformationally biased, agonist of human C5a65-74 (EP67) was assessed for its adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) type cytokines from C5a receptor (CD88)-bearing antigen presenting cells (APC). EP67 did not induce the release of these cytokines from splenic APCs obtained from C5a receptor knockouts (CD88-/-). Serum from mice immunized with EP67-ovalbumin (OVA) contained high OVA-specific antibody (Ab) titers [IgG1, IgG2a (IGg2c), IgG2b]. Mice receiving OVA alone produced only IgG1 Abs, indicating the ability of EP67 to induce a Th1-like Ab class switch. Spleen cell cultures from wild type mice but not CD88-/- mice showed an enhanced OVA-specific proliferative response in vitro. These results indicate the ability of EP67 to drive a Th1-mediated immune response and its potential use as a unique adjuvant.",
keywords = "Adjuvants, Antibodies, C5a, Vaccines",
author = "Morgan, {Edward L.} and Morgan, {Brandon N.} and Stein, {Elisabeth A.} and Vitrs, {Elizabeth L.} and Thoman, {Marilyn L.} and Sam Sanderson and Phillips, {Joy A.}",
year = "2009",
month = "12",
day = "11",
doi = "10.1016/j.vaccine.2009.10.029",
language = "English (US)",
volume = "28",
pages = "463--469",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a

T2 - Implications for a novel adjuvant in vaccine design

AU - Morgan, Edward L.

AU - Morgan, Brandon N.

AU - Stein, Elisabeth A.

AU - Vitrs, Elizabeth L.

AU - Thoman, Marilyn L.

AU - Sanderson, Sam

AU - Phillips, Joy A.

PY - 2009/12/11

Y1 - 2009/12/11

N2 - A conformationally biased, agonist of human C5a65-74 (EP67) was assessed for its adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) type cytokines from C5a receptor (CD88)-bearing antigen presenting cells (APC). EP67 did not induce the release of these cytokines from splenic APCs obtained from C5a receptor knockouts (CD88-/-). Serum from mice immunized with EP67-ovalbumin (OVA) contained high OVA-specific antibody (Ab) titers [IgG1, IgG2a (IGg2c), IgG2b]. Mice receiving OVA alone produced only IgG1 Abs, indicating the ability of EP67 to induce a Th1-like Ab class switch. Spleen cell cultures from wild type mice but not CD88-/- mice showed an enhanced OVA-specific proliferative response in vitro. These results indicate the ability of EP67 to drive a Th1-mediated immune response and its potential use as a unique adjuvant.

AB - A conformationally biased, agonist of human C5a65-74 (EP67) was assessed for its adjuvant activities in vitro and in vivo. EP67 induced the release of the inflammatory (Th1) type cytokines from C5a receptor (CD88)-bearing antigen presenting cells (APC). EP67 did not induce the release of these cytokines from splenic APCs obtained from C5a receptor knockouts (CD88-/-). Serum from mice immunized with EP67-ovalbumin (OVA) contained high OVA-specific antibody (Ab) titers [IgG1, IgG2a (IGg2c), IgG2b]. Mice receiving OVA alone produced only IgG1 Abs, indicating the ability of EP67 to induce a Th1-like Ab class switch. Spleen cell cultures from wild type mice but not CD88-/- mice showed an enhanced OVA-specific proliferative response in vitro. These results indicate the ability of EP67 to drive a Th1-mediated immune response and its potential use as a unique adjuvant.

KW - Adjuvants

KW - Antibodies

KW - C5a

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=70649089218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649089218&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.10.029

DO - 10.1016/j.vaccine.2009.10.029

M3 - Article

VL - 28

SP - 463

EP - 469

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 2

ER -